Latest News Highlights: COVID-19 VAX💉 Study📊SPONSORED POST: C L I C K H E R E COVID-19 challenge study • Variants have become the established infection model, which can be better addressed with Vaxil’s SP approach
• “Thanks to our relatively strong balance sheet, we have sufficient funds to continue the pre-clinical development of our potential vaccine and our other research programs,”said David Goren, Vaxil’s Chairman and Chief Executive Officer.
• Vaxil will evaluate alternate peptide delivery approaches, including oral administration.